Cargando…

Evaluation of Event-Free Survival Surrogating Overall Survival as the Endpoint in Neoadjuvant Clinical Trials of Gastroesophageal Adenocarcinoma

BACKGROUND: Gastric cancer (GC) is one of the most common malignant cancers worldwide. The development of potential antitumor agents is being investigated and stimulates more clinical trials. Overall survival (OS) is consistently considered the primary endpoint for clinical trials on treatment effec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Hua, Wang, Yakun, Qi, Changsong, Xie, Tong, Peng, Zhi, Li, Jian, Shen, Lin, Zhang, Xiaotian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9022778/ https://www.ncbi.nlm.nih.gov/pubmed/35463354 http://dx.doi.org/10.3389/fonc.2022.835389

Ejemplares similares

Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials
por: Wang, Zi-Xian, et al.
Publicado: (2021)

Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic colorectal cancer
por: Cicero, Giuseppe, et al.
Publicado: (2018)

Interpretation of meta-analysis evaluating progression-free survival as a surrogate endpoint for overall survival in glioblastoma
por: Han, Kelong, et al.
Publicado: (2015)

Identification on surrogating overall survival with progression-free survival of first-line immunochemotherapy in advanced esophageal squamous cell carcinoma—an exploration of surrogate endpoint
por: Zhang, Zewei, et al.
Publicado: (2023)

Consideration of Surrogate Endpoints for Overall Survival Associated With First-Line Immunotherapy in Extensive-Stage Small Cell Lung Cancer
por: Zhang, Shuang, et al.
Publicado: (2021)

Progression-Free Survival and Time to Progression as Potential Surrogate Endpoints for Overall Survival in Chemoradiotherapy Trials in Limited-Stage Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: Yang, Yin, et al.
Publicado: (2022)

Correlation between pathologic complete response, event-free survival/disease-free survival and overall survival in neoadjuvant and/or adjuvant HR+/HER2-breast cancer
por: Gogate, Anagha, et al.
Publicado: (2023)

Corrigendum: Progression-free survival and time to progression as potential surrogate endpoints for overall survival in chemoradiotherapy trials in limited-stage small-cell lung cancer: A systematic review and meta-analysis
por: Yang, Yin, et al.
Publicado: (2022)

Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology
por: Sherrill, Beth, et al.
Publicado: (2012)

Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysis
por: Sjoquist, Katrin M., et al.
Publicado: (2018)

Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma
por: Cabibbo, Giuseppe, et al.
Publicado: (2020)

Surrogate Endpoints for Overall Survival in Immune-Oncology Trials of Advanced Gastro-Esophageal Carcinoma
por: Li, Yuan Fang, et al.
Publicado: (2022)

Neoadjuvant chemotherapy for borderline resectable and upfront resectable pancreatic cancer increasing overall survival and disease-free survival?
por: Fossaert, Violette, et al.
Publicado: (2022)

Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials
por: Han, Kelong, et al.
Publicado: (2014)

Progression-free survival as a surrogate endpoint for overall survival in patients with third-line or later-line chemotherapy for advanced gastric cancer
por: Liu, Liya, et al.
Publicado: (2015)

Searching for potential surrogate endpoints of overall survival in clinical trials for patients with prostate cancer
por: Maeda, Hideki, et al.
Publicado: (2021)

Progression-Free Survival as Early Efficacy Endpoint in Resectable Esophageal Cancer Treated With Neoadjuvant Therapy: A Systematic Review
por: Zhu, Jie, et al.
Publicado: (2022)

Progression-free survival as surrogate endpoint of overall survival in esophageal squamous cell carcinoma: a real-world data and literature-based analysis
por: Han, Weiming, et al.
Publicado: (2022)

Evaluating relapse-free survival as an endpoint for overall survival in adjuvant immunotherapy trials
por: Li, Yuanfang, et al.
Publicado: (2023)

Validation of Minimal Residual Disease as Surrogate Endpoint for Event-Free Survival in Childhood Acute Lymphoblastic Leukemia
por: Galimberti, Stefania, et al.
Publicado: (2018)

Surrogate Endpoints as Predictors of Overall Survival in Metastatic Urothelial Cancer: A Trial-level Analysis
por: Ghali, Fady, et al.
Publicado: (2022)

Disease-free survival as a surrogate endpoint for overall survival in adjuvant trials of pancreatic cancer: a meta-analysis of 20 randomized controlled trials
por: Nie, Run-Cong, et al.
Publicado: (2020)

A systematic review of meta-analyses assessing the validity of tumour response endpoints as surrogates for progression-free or overall survival in cancer
por: Cooper, Katy, et al.
Publicado: (2020)

Surrogate endpoints for overall survival in randomised controlled trials of localised osteosarcoma: A meta-analytic evaluation
por: Tanaka, Kazuhiro, et al.
Publicado: (2020)

Survival benefit after neoadjuvant or adjuvant radiotherapy for stage II–III gastroesophageal junction adenocarcinoma: A large population-based cohort study
por: Zuo, Zhichao, et al.
Publicado: (2022)

Progression-free survival as a potential surrogate for overall survival in metastatic breast cancer
por: Beauchemin, Catherine, et al.
Publicado: (2014)

Circulating Cell-Free Tumor DNA in Advanced Pancreatic Adenocarcinoma Identifies Patients With Worse Overall Survival
por: Botrus, Gehan, et al.
Publicado: (2022)

A Novel Nomogram Model to Predict the Recurrence-Free Survival and Overall Survival of Hepatocellular Carcinoma
por: Zhang, Shu-Wen, et al.
Publicado: (2022)

Combination of clinical, radiomic, and “delta” radiomic features in survival prediction of metastatic gastroesophageal adenocarcinoma
por: Krishna, Satheesh, et al.
Publicado: (2023)

A correlation analysis to assess event-free survival as a trial-level surrogate for overall survival in early breast cancer
por: Gyawali, Bishal, et al.
Publicado: (2021)

Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma
por: Nie, Run-Cong, et al.
Publicado: (2020)

Surrogate endpoints for overall survival in digestive oncology trials: which candidates? A questionnaires survey among clinicians and methodologists
por: Methy, Nicolas, et al.
Publicado: (2010)

Potential surrogate endpoints for overall survival in locoregionally advanced nasopharyngeal carcinoma: an analysis of a phase III randomized trial
por: Chen, Yu-Pei, et al.
Publicado: (2015)

Prognostic Nomograms for Predicting Overall Survival and Cancer-Specific Survival of Patients With Early Onset Colon Adenocarcinoma
por: Jin, Huimin, et al.
Publicado: (2020)

Correlation Between Early Endpoints and Overall Survival in Non-Small-Cell Lung Cancer: A Trial-Level Meta-Analysis
por: Shameer, Khader, et al.
Publicado: (2021)

Validation of Progression‐Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials
por: Wang, Xiaofei, et al.
Publicado: (2017)

Corrigendum: Prognostic Nomograms for Predicting Overall Survival and Cancer-Specific Survival of Patients With Early Onset Colon Adenocarcinoma
por: Jin, Huimin, et al.
Publicado: (2021)

Progression-free survival as a surrogate for overall survival in oncology trials: a methodological systematic review
por: Belin, Lisa, et al.
Publicado: (2020)

Systematic Review and Meta-Analysis of Correlation of Progression-Free Survival-2 and Overall Survival in Solid Tumors
por: Chowdhury, Simon, et al.
Publicado: (2020)

Prognostic nomogram that predicts progression-free survival and overall survival of patients with ovarian clear cell carcinoma
por: Li, Jiayi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_a1hf2gankhsooonpe564to2k0u